JPWO2022186349A1 - - Google Patents

Info

Publication number
JPWO2022186349A1
JPWO2022186349A1 JP2022539639A JP2022539639A JPWO2022186349A1 JP WO2022186349 A1 JPWO2022186349 A1 JP WO2022186349A1 JP 2022539639 A JP2022539639 A JP 2022539639A JP 2022539639 A JP2022539639 A JP 2022539639A JP WO2022186349 A1 JPWO2022186349 A1 JP WO2022186349A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022539639A
Other languages
Japanese (ja)
Other versions
JPWO2022186349A5 (https=
JP7233147B2 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2022186349A1 publication Critical patent/JPWO2022186349A1/ja
Publication of JPWO2022186349A5 publication Critical patent/JPWO2022186349A5/ja
Priority to JP2023020860A priority Critical patent/JP2023058660A/ja
Application granted granted Critical
Publication of JP7233147B2 publication Critical patent/JP7233147B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022539639A 2021-03-04 2022-03-03 リンパ管新生促進因子発現線維芽細胞及びそれを含む医薬組成物 Active JP7233147B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023020860A JP2023058660A (ja) 2021-03-04 2023-02-14 リンパ管新生促進因子発現線維芽細胞及びそれを含む医薬組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2021034018 2021-03-04
JP2021034018 2021-03-04
JP2021034016 2021-03-04
JP2021034016 2021-03-04
PCT/JP2022/009205 WO2022186349A1 (ja) 2021-03-04 2022-03-03 リンパ管新生促進因子発現線維芽細胞及びそれを含む医薬組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023020860A Division JP2023058660A (ja) 2021-03-04 2023-02-14 リンパ管新生促進因子発現線維芽細胞及びそれを含む医薬組成物

Publications (3)

Publication Number Publication Date
JPWO2022186349A1 true JPWO2022186349A1 (https=) 2022-09-09
JPWO2022186349A5 JPWO2022186349A5 (https=) 2023-02-01
JP7233147B2 JP7233147B2 (ja) 2023-03-06

Family

ID=83155368

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022539639A Active JP7233147B2 (ja) 2021-03-04 2022-03-03 リンパ管新生促進因子発現線維芽細胞及びそれを含む医薬組成物
JP2023020860A Withdrawn JP2023058660A (ja) 2021-03-04 2023-02-14 リンパ管新生促進因子発現線維芽細胞及びそれを含む医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023020860A Withdrawn JP2023058660A (ja) 2021-03-04 2023-02-14 リンパ管新生促進因子発現線維芽細胞及びそれを含む医薬組成物

Country Status (8)

Country Link
US (1) US20240148795A1 (https=)
EP (1) EP4302771A4 (https=)
JP (2) JP7233147B2 (https=)
KR (1) KR20230154177A (https=)
AU (1) AU2022231584A1 (https=)
CA (1) CA3211113A1 (https=)
IL (1) IL305069A (https=)
WO (1) WO2022186349A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240316113A1 (en) * 2021-09-08 2024-09-26 Metcela Inc. Fibroblast-containing pharmaceutical composition for treating kidney disease
JP2025515887A (ja) 2022-11-11 2025-05-20 エルジー エナジー ソリューション リミテッド 負極活物質、これを含む負極、これを含む二次電池、および負極活物質の製造方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020045547A1 (ja) * 2018-08-29 2020-03-05 株式会社メトセラ 線維芽細胞の製造方法及びｇ－ｃｓｆ陽性線維芽細胞集団

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102407387B1 (ko) * 2017-02-24 2022-06-10 가부시키가이샤 메토세라 섬유아세포를 포함하고, 심장 질환들의 치료를 위하여 사용될 수 있는 주사용 조성물, 및 치료 용도를 위하여 섬유아세포를 생산하는 방법
US20240316113A1 (en) * 2021-09-08 2024-09-26 Metcela Inc. Fibroblast-containing pharmaceutical composition for treating kidney disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020045547A1 (ja) * 2018-08-29 2020-03-05 株式会社メトセラ 線維芽細胞の製造方法及びｇ－ｃｓｆ陽性線維芽細胞集団

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DUNWORTH ,W. P. ET AL.: "Adrenomedullin stabilizes the lymphatic endothelial barrier in vitro and in vivo.", PEPTIDES, vol. 29, JPN6022015378, 2008, pages 2243 - 2249, XP025673190, ISSN: 0004966600, DOI: 10.1016/j.peptides.2008.09.009 *
KACH, J. ET AL.: "Regulation of myofibroblast differentiation and bleomycin-induced pulmonary fibrosis by adrenomedull", AM. J. PHYSIOL. LUNG CELL MOL. PHYSIOL., vol. 304 (11), JPN6022015382, 2013, pages 757 - 764, ISSN: 0004966598 *
KONG, F. ET AL.: "Exosomal adrenomedullin derived from cancer-associated fibroblasts promotes lipolysis in adipose tis", GUT, vol. 67 (12), JPN6022015380, 2018, pages 2226 - 2227, ISSN: 0004966599 *

Also Published As

Publication number Publication date
WO2022186349A1 (ja) 2022-09-09
JP2023058660A (ja) 2023-04-25
EP4302771A1 (en) 2024-01-10
AU2022231584A1 (en) 2023-09-07
KR20230154177A (ko) 2023-11-07
IL305069A (en) 2023-10-01
US20240148795A1 (en) 2024-05-09
JP7233147B2 (ja) 2023-03-06
EP4302771A4 (en) 2025-04-02
CA3211113A1 (en) 2022-09-09

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
JPWO2022186349A1 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021007058A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021015220A2 (https=)
BR102021014044A2 (https=)
BR102021014056A2 (https=)
BR102021013929A2 (https=)
BR102021012571A2 (https=)
BR102021012230A2 (https=)
BR102021012107A2 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220707

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220707

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220707

AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20220719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230117

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230214

R150 Certificate of patent or registration of utility model

Ref document number: 7233147

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250